Eucafluff Expands Businesses in Europe, Asia, and in the United States
11.4.2019 09:00:00 EEST | Business Wire | Press release
Suzano (NYSE:SUZ), a merger between Suzano Papel e Celulose and Fibria, has increased Eucafluff sales in the European, Asian, and US markets. The product is the only eucalyptus-based fluff pulp sold in the world and is used in personal hygiene items such as diapers and sanitary napkins. Eucafluff is considered a reference of innovation and sustainability and, therefore, has been approved by major global manufacturers. In the last 6 months, companies such as Ontex and Vinda International, amongst other local players in Europe, the United States, Japan, and China have been buying from Suzano.
Currently, 86% of Eucafluff's sales are made overseas, in which 25% are sold in Europe. "The acceptance of our fluff pulp in mature markets and multinational companies has confirmed the good performance that eucalyptus fiber can also bring to the hygiene market. We are committed to improving the quality and performance of our client’s end products and this has reflected in the global partnerships we have achieved these past months, " says Alexandre Corrêa, Executive Manager of the Business Unit at Suzano.
Developed by Suzano and resulting from 11 years of research, Eucafluff is the first bleached kraft pulp of eucalyptus fluff type in the world, and is be applied in absorbent products as well as personal hygiene products, disposables like children and adults diapers, sanitary napkins for women, amongst other applications. The key benefits provided by this unique fiber are a higher liquid absorption and retention at product cores and greater comfort and discretion to the end user, such as in the case of application in incontinence pants. These benefits are due to the greater compressibility of the eucalyptus fiber, a feature that has also brought other associated benefits as reduction in packaging size, transportation, and storage costs.
Suzano has 95 years of history and 11 factories, and is present in the lives of more than 2 billion people through its products. The company is the world´s leader in the production of eucalyptus pulp, a raw material developed by the company in the 1960s, is also a world pioneer in the production of eucalyptus fluff and is one of the largest paper manufacturers in Latin America. Since its inception, it has invested in innovative and unique solutions, seeking the substitution of raw materials of fossil origin for other sources of renewable origin.
About Suzano
Suzano , the company resulting from the merger of Suzano Pulp & Paper and Fibria, is committed to being a global reference in the sustainable use of natural resources. The world's leading producer of eucalyptus pulp and one of Latin America’s largest paper producers, Suzano exports to more than 80 countries and, through its products, plays a part in the lives of over two billion people. With ten mills and the joint operation Veracel, Suzano has annual installed capacity of 11 million tons of market pulp and 1.4 million tons of paper. Suzano has approximately 37,000 direct and indirect employees and for over 90 years has invested in innovative solutions based on eucalyptus cultivation that enable it to substitute the use of fossil-based materials with renewable bio-based materials. The company adopts the highest standards of corporate governance on the exchanges where its stock is traded, namely the B3 in Brazil and the NYSE in the United States.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190410005839/en/
Contact information
PLANIN – Suzano’s PR Agency
Angélica Consiglio, Beatriz
Imenes and team – www.planin.com
E-mail:
suzano@planin.com - Phone: +55
(11) 2138-8940
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
